Abstract 1402
Background
Neoadjuvant chemotherapy is promising to improve the survival of locally advanced gastric cancer. However, optimal regimen and duration of treatment have not been established. We previously reported the primary results of COMPASS-D trial (ASCO-GI 2019). Herein, we report the results of subgroup analyses of efficacy by baseline disease characteristics and demographics.
Methods
Patients with M0 and either T4 or T3 in case of junctional cancer or schirrhous type received 2 or 4 courses of cisplatin (60 mg/m2 at day 8) / S-1 (80 mg/m2 for 21 days with 1 week rest) or docetaxel (40 mg/m2 at day 1) / cisplatin (60 mg/m2 at day 1) / S-1 (80 mg/m2 for 14 days with 2 weeks rest) as neoadjuvant chemotherapy. Then, patients underwent D2 gastrectomy and adjuvant S-1 chemotherapy for 1 year. The primary endpoint was 3-year overall survival. Subgroup analysis was performed in each regimen (CS vs DCS) and duration (2 vs 4 courses), stratified by age, gender, esophageal invasion, macroscopic type, histological type, cT, and cN.
Results
Between Oct 2011 and Sep 2014, 132 patients were assigned to CS (n = 66; 33 in 2-courses and 33 in 4-courses) and DCS (n = 66; 33 in 2-courses and 33 in 4-courses). The 3-year OS was 58.1% in 2-courses CS, 58.1% in 4-courses CS, 48.5% in 2-courses DCS, and 71.9% in 4-courses DCS. Subgroup analyses were summarized in the table.Table:
778P
Subgroup | HR of 4-sourses (95%CI) | HR of DCS (95%CI) |
---|---|---|
Overall | 0.77 (0.43-1.22) | 0.80 (0.48-1.34) |
Age < 70 y.o. | 0.82 (0.45-1.52) | 0.88 (0.48-1.62) |
Age = > 70 y.o. | 0.49 (0.17-1.39) | 0.68 (0.26-1.76) |
Male | 0.53 (0.27-1.05) | 0.81 (0.42-1.54) |
Female | 1.22 (0.51-2.90) | 0.79 (0.33-1.87) |
Esophageal invasion- | 0.72 (0.40-1.31) | 0.71 (0.39-1.27) |
Esophageal invasion+ | 0.73 (0.24-2.17) | 1.06 (0.36-3.16) |
Schirrhous or large Type3 | 0.47 (0.22-1.00) | 0.82 (0.41-1.63) |
Non schirrous or large Type3 | 0.74 (0.23-2.41) | 0.50 (0.13-1.87) |
Differentiated | 0.37 (0.08-1.66) | 0.38 (0.09-1.71) |
Undiffirentiated | 0.66 (0.32-1.36) | 1.24 (0.63-2.43) |
cT3 or T4a | 0.66 (0.38-1.17) | 0.76 (0.44-1.32) |
cT4b | N/A | 2.33 (0.26-21.4) |
cN0 | 0.77 (0.32-1.86) | 0.74 (0.31-1.80) |
cN + | 0.66 (0.34-1.27) | 0.87 (0.46-1.66) |
Conclusions
The DCS regimen and duration 4-courses showed a beneficial tendency as a neoadjuvant setting regardless of disease characteristics and demographics. The 4-courses DCS is widely applicable to future phase III study to confirm of neoadjuvant chemotherapy for locally advanced gastric cancer.
Clinical trial identification
UMIN000006378.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Nongovermental Organization, Kanagawa Standard Anti-cancer Therapy Support System.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3392 - Post-hoc analysis of the nintedanib exposure-response relationships in the CHIVA trial in advanced ovarian cancer: (a GINECO study)
Presenter: Skerdi HAVIARI
Session: Poster Display session 2
Resources:
Abstract
714 - The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian insufficiency in patient with malignant ovarian germ cell tumors
Presenter: Min Kyu Kim
Session: Poster Display session 2
Resources:
Abstract
1753 - Ex vivo cytotoxicity and in vivo antitumor activity of a novel highly selective STAT3 inhibitor YHO-1701 for ovarian and endometrial cancer
Presenter: Kosei Hasegawa
Session: Poster Display session 2
Resources:
Abstract
3739 - Mutational landscapes and tumor mutational burden expression in endometrial cancer
Presenter: Yingli Zhang
Session: Poster Display session 2
Resources:
Abstract
2109 - Clinical features and frequency of mismatch repair protein deficiency in ovarian clear cell and endometrioid carcinoma patients.
Presenter: Kazuhiro Takehara
Session: Poster Display session 2
Resources:
Abstract
4554 - Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer
Presenter: Lea Moukarzel
Session: Poster Display session 2
Resources:
Abstract
3645 - Cancer-specific survival with or without adjuvant chemotherapy in high-risk stage I endometrial cancer
Presenter: Jenny Ko
Session: Poster Display session 2
Resources:
Abstract
3394 - Pembrolizumab in Patients with MSI-H Advanced Endometrial Cancer from the KEYNOTE-158 Study
Presenter: David Omalley
Session: Poster Display session 2
Resources:
Abstract
3388 - Who drops out of cervical cancer screening? Results from the EDIFICE 6 survey
Presenter: Thibault de La Motte Rouge
Session: Poster Display session 2
Resources:
Abstract
2485 - Identification of a RNA-Seq Based Signature to Improve Prognostic for Uterine Sarcoma
Presenter: Jian-Guo Zhou
Session: Poster Display session 2
Resources:
Abstract